Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

BET Inhibition ▼CV Inflammation ▼Diabetes & CVD ▼ESC 2018 ▼Expert Meeting GLP-1, CVD & T2DM ▼Invest in your arteries ▼PCSK9 ▼

CVMC

Slides (curriculum) - May 9, 2013

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

Very early invasive investigation does not improve long-term outcome when NSTEMI ACS is suspected

News - Aug. 28, 2018

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Atherosclerosis

Interference with the interleukin-6 pathway associated with lower risk of CV events

Literature - Sep. 12, 2018 - Ridker PM et al. - Eur Heart J 2018

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK

Higher smoking exposure and alcohol consumption associated with increased arterial stiffness in adolescents

Literature - Sep. 4, 2018 - Charakida M, et al. - Eur Heart J 2018

Atrial fibrillation

NOAC during AF ablation associated with reduced risk of adverse outcomes

Literature - Sep. 17, 2018 - Kirchhof P et al. - Eur Heart J 2018

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke

Literature - July 26, 2018 - Go AS, et al. - JAMA Cardiol. 2018

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

BET Inhibition

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden

CV Inflammation

Interference with the interleukin-6 pathway associated with lower risk of CV events

Literature - Sep. 12, 2018 - Ridker PM et al. - Eur Heart J 2018

Low testosterone/estradiol ratio associated with higher CV risk in men with atherosclerotic disease

Literature - July 30, 2018 - Koeverden ID, et al. - Cardiovasc Res 2018

Yogurt consumption before an unhealthy meal reduces postprandial inflammation

Literature - May 24, 2018 - Pei R, et al. - J Nutr 2018

CVRM

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

Reduced CV disease and mortality with higher healthy diet score worldwide

News - Aug. 28, 2018

Clinical Updates in the Management of Cardiovascular Risk 2018

Online-CME - Online-CME - This course consists of 4 separate lectures

Diabetes

Slides: GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - Filip K Knop, MD – Copenhagen, Denmark

Slides: Diabetes & CVD: Time for a multifactorial approach

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - John Deanfield, MD - London, UK

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Diabetes & CVD

Glucagon-like peptide-1 analogue promotes weight loss in obese, non-diabetic individuals

Literature - Sep. 12, 2018 - O’Neil PM et al. - The Lancet 2018

Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction

Online-CME - Online-CME - This course consists of 3 separate lectures

Slides: GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - Filip K Knop, MD – Copenhagen, Denmark

ESC 2018

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

ESC debate | First-line therapies in HFrEF - ACE inhibitors or sacubitril/valsartan?

ESC 2018 - debates

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Clinical genetic testing provides improved diagnosis of FH

News - Aug. 13, 2018

Oral microsomal triglyceride transfer protein inhibitor is beneficial in HoFH

Literature - June 28, 2018 - Blom DJ, et al. - Orphanet J Rare Dis 2018

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

GLP-1 RA & CVD

Glucagon-like peptide-1 analogue promotes weight loss in obese, non-diabetic individuals

Literature - Sep. 12, 2018 - O’Neil PM et al. - The Lancet 2018

Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction

Online-CME - Online-CME - This course consists of 3 separate lectures

Slides: GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - Filip K Knop, MD – Copenhagen, Denmark

Heart Failure

New ESC guidelines on management of CVD during pregnancy

News - Sep. 14, 2018

ESC debate | First-line therapies in HFrEF - ACE inhibitors or sacubitril/valsartan?

ESC 2018 - debates

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Hypertension

ESC Debate | Should hypertension be redefined?

ESC 2018 - debates

2018 ESC/ESH Guidelines for management of arterial hypertension

News - Aug. 27, 2018

Clinical Updates in the Management of Cardiovascular Risk 2018

Online-CME - Online-CME - This course consists of 4 separate lectures

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Lipids

ApoC-III distribution in lipoproteins does not provide incremental predictive value for CAD

Literature - Sep. 18, 2018 - van Capelleveen JC et al. - J Clin Lipidol 2018; published online ahead of print

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Combination pill with inhibitors of cholesterol synthesis and absorption met primary endpoint

News - Sep. 3, 2018

Lp(a)

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Clinical genetic testing provides improved diagnosis of FH

News - Aug. 13, 2018

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

No overall benefit of use of aspirin in primary prevention setting in diabetes patients and individuals with moderate CV risk

News - Aug. 26, 2018

Stepwise reduced CV risk with each risk factor variable within target range in T2DM patients

Literature - Aug. 21, 2018 - Rawshani A et al. - N Engl J Med 2018

© 2006 - 2018 pace-cme.org - About